ReplimuneREPL
NASDAQBiotech
No cached AI snapshot yet for REPL.
Be the first to run a multi-agent analysis on this ticker.
Key Stats
479 employees82.57M shares outstandinglisted 2018-07-20
Next earnings ~May 5, 2026
About Replimune
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
Latest News
Showing market-wide stock news
Replimune Group, Inc. (REPL) Shareholder/Analyst Call Prepared Remarks Transcript
REPL Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Replimune Group, Inc. Securities Lawsuit - Contact Levi & Korsinsky
Euro: 1.150 target nears on Fed risk against US Dollar – ING
WTI falls near $100 as Saudi adds Oman route, US stocks surge
Yield on 10-year Treasury hovers above 5% as investors await Fed decision
USD/JPY Price Forecast: Retreats from 155.50 with Fed’s policy in focus
Related Stocksin Biotech
Ready to see the live AI view on REPL?
Launch a real-time multi-agent room — Claude, GPT, Gemini, DeepSeek, Grok, and Qwen analyzing REPL side-by-side with live signals.